|
시장보고서
상품코드
2091310
임신성 당뇨병 시장 규모, 점유율, 성장 분석 : 진단 유형별, 치료 유형별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Gestational Diabetes Market Size, Share, and Growth Analysis, By Diagnosis Type (Oral Glucose Tolerance Test (OGTT), Fasting Blood Sugar Test), By Treatment Type, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 임신성 당뇨병 시장 규모는 2024년에 92억 1,000만 달러로 평가되었으며, 2025년 100억 5,000만 달러에서 2033년까지 201억 6,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 9.1%로 성장할 것으로 전망됩니다.
세계 임신성 당뇨병(GDM) 시장은 임산부와 영아 모두에게 심각한 위험을 초래하는 임신 중 당내성 이상 유병률의 증가에 힘입어 급속히 성장하고 있습니다. 이러한 성장 가속화에는 비만, 출산 연령의 고령화, 인구 동향의 변화와 같은 요인들이 영향을 미치고 있으며, 위험에 처한 사람들의 수가 증가하고 있습니다. 디지털 헬스 솔루션은 이러한 시장 확대에 있어 매우 중요한 역할을 하고 있으며, 효과적인 데이터 공유를 가능하게함으로써 의료진이 인슐린 요법을 신속하게 조정하고 치료 성과를 향상시킬 수 있습니다. 애보트(Abbott)나 덱스콤(Dexcom)과 같은 기업들이 제공하는, 임신 기간에 특화된 지속 혈당 모니터링 기술의 혁신은 보험 적용 대상이 되어가고 있으며, 이는 병원들이 원격의료 인프라에 대한 투자를 확대하는 계기가 되고 있습니다. 이러한 역동적인 생태계는 수익원을 확대할 뿐만 아니라, GDM 관리를 정기 산전 검진에 포함시키도록 공공 정책의 전환을 촉진하고 있습니다.
세계 임신성 당뇨병 시장의 성장요인
임산부들 사이에서 임신성 당뇨병에 대한 인식이 높아지면서, 선별 검사 및 관리 솔루션에 대한 수요가 크게 증가하고 있습니다. 임산부가 더 많은 정보를 얻고 산전 관리에 적극적으로 임하게 됨에 따라, 의료 서비스 제공자들은 종합적인 검사 절차와 맞춤형 치료 계획을 도입하여 이에 대응하고 있습니다. 이러한 변화로 인해 진단 기기, 혈당 모니터링 시스템 및 다양한 치료 서비스 시장이 확대되고 있습니다. 또한, 환자의 참여도가 높아짐에 따라 원격 모니터링을 가능하게 하는 디지털 헬스 플랫폼의 활용이 확대되고 있습니다. 이를 통해 환자의 치료 성과와 만족도를 높일 뿐만 아니라, 임신성 당뇨병 시장에서 지속적인 성장과 지속가능성을 확보하는, 보다 광범위한 생태계가 형성되고 있습니다.
세계 임신성 당뇨병 시장의 제약요인
세계 임신성 당뇨병 시장의 성장은 제한적인 보험 급여 정책으로 인해 저해되고 있습니다. 의료보험사들은 이 질환과 관련된 의료기기나 서비스를 '비필수' 또는 '선택적'으로 분류하는 경우가 많기 때문입니다. 이러한 분류는 의료 제공자에게 불확실성을 야기하여, 전액 환급되는 기존의 저비용 대안을 우선시함으로써 첨단 모니터링 기술의 도입을 주저하게 할 가능성이 있습니다. 이러한 주저함은 혁신적인 솔루션에 대한 수요를 위축시키고, 신제품 개발에 대한 투자를 저해합니다. 그 결과, 제조사는 판매망 확대에 있어 장벽에 직면하게 되고, 보다 명확한 자금 조달 수단이 마련될 때까지 신제품 출시를 연기할 수밖에 없게 되며, 결국 시장 확대가 저해되게 됩니다. 또한, 환자가 부담하는 본인부담금으로 인해 권장되는 치료법을 준수하는 데 제약이 생길 수 있으며, 이는 시장 전체의 보급률에 추가적인 영향을 미칩니다.
세계 임신성 당뇨병 시장의 동향
세계 임신성 당뇨병 시장은 환자 관리에 맞춤형 영양 전략이 도입됨에 따라 크게 발전하고 있습니다. 의료 종사자들이 지속 혈당 모니터링 데이터를 활용해 맞춤형 식단 계획을 수립하는 사례가 늘어나고 있으며, 환자 개개인의 고유한 대사 반응에 따라 3대 영양소의 구성과 식사 시간을 최적화할 수 있게 되었습니다. 이러한 변화는 혈당 조절을 개선하고 태아의 건강한 성장을 돕습니다. 영양 기술 플랫폼의 발전에 따라 실시간 피드백과 예측적 인사이트이 제공되면서, 환자의 참여와 식이요법 준수가 촉진되고 있습니다. 그 결과, 영양에 중점을 둔 전략은 임산부의 건강 목표에 부합하는 포괄적이고 성과 중심의 진료를 제공하는 의료 서비스 제공자에게 있어 필수적인 차별화 요소로 자리 잡고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 임신성 당뇨병 시장 규모 : 진단 유형별
세계의 임신성 당뇨병 시장 규모 : 치료 유형별
세계의 임신성 당뇨병 시장 규모 : 최종사용자별
세계의 임신성 당뇨병 시장 규모 : 유통 채널별
세계의 임신성 당뇨병 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Gestational Diabetes Market size was valued at USD 9.21 Billion in 2024 and is poised to grow from USD 10.05 Billion in 2025 to USD 20.16 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
The global gestational diabetes mellitus (GDM) market is rapidly evolving, driven by the rising prevalence of glucose intolerance during pregnancy which poses significant risks to both mothers and infants. This accelerating growth is influenced by factors such as obesity, delayed childbearing, and changing demographic trends, increasing the number of at-risk individuals. Digital health solutions play a crucial role in this market expansion, enabling effective data sharing that allows healthcare providers to adjust insulin therapies swiftly and improve health outcomes. Innovations in continuous glucose monitoring tailored for pregnancy from companies like Abbott and Dexcom are attracting insurance reimbursement, prompting hospitals to invest in telehealth infrastructure. This dynamic ecosystem not only enhances revenue avenues but also fosters shifts in public policy to integrate GDM management into routine prenatal care.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gestational Diabetes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Gestational Diabetes Market Segments Analysis
Global gestational diabetes market is segmented by diagnosis type, treatment type, end user, distribution channel and region. Based on diagnosis type, the market is segmented into Oral Glucose Tolerance Test (OGTT), Fasting Blood Sugar Test, Random Blood Sugar Test and Hemoglobin A1c (HbA1c) Test. Based on treatment type, the market is segmented into Dietary Changes & Lifestyle Modification, Insulin Therapy, Oral Medications, Continuous Glucose Monitoring (CGM) and Physical Activity Programs. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Homecare Settings and Maternity Clinics. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Gestational Diabetes Market
The rising awareness among expectant mothers regarding gestational diabetes is significantly boosting the demand for screening and management solutions. As mothers-to-be become more informed and proactive in their prenatal care, healthcare providers are adapting by introducing comprehensive testing protocols and tailored treatment plans. This evolution enhances the market for diagnostic devices, glucose monitoring systems, and various therapeutic services. Additionally, increased engagement from patients promotes the use of digital health platforms that enable remote monitoring. This creates a more extensive ecosystem that not only improves patient outcomes and satisfaction but also ensures sustained growth and sustainability within the gestational diabetes market.
Restraints in the Global Gestational Diabetes Market
The growth of the global gestational diabetes market is hindered by restrictive reimbursement policies, as healthcare payers frequently categorize devices and services related to this condition as non-essential or elective. This classification creates uncertainty for providers, who may be reluctant to adopt advanced monitoring technologies in favor of traditional, lower-cost alternatives that are fully reimbursed. Such hesitance dampens demand for innovative solutions and hampers investment in new product development. As a result, manufacturers face obstacles in scaling their distribution efforts and may postpone launching new offerings until clearer funding options arise, ultimately stifling market expansion. Additionally, out-of-pocket expenses incurred by patients can limit adherence to recommended treatments, which further impacts overall market uptake.
Market Trends of the Global Gestational Diabetes Market
The Global Gestational Diabetes market is evolving significantly with the integration of personalized nutrition strategies in patient management. Healthcare providers are increasingly utilizing continuous glucose monitoring data to develop individualized dietary plans, allowing for tailored macronutrient compositions and meal timing based on each patient's unique metabolic response. This shift enhances glycemic control and supports healthy fetal development. As nutrition technology platforms advance, they provide real-time feedback and predictive insights that encourage patient engagement and adherence to dietary regimens. Consequently, nutrition-focused strategies are becoming essential differentiators for providers delivering comprehensive, outcomes-oriented care aligned with maternal health objectives.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Gestational Diabetes Market Size by Diagnosis Type & CAGR (2026-2033)
- Market Overview
- Oral Glucose Tolerance Test (OGTT)
- Fasting Blood Sugar Test
- Random Blood Sugar Test
- Hemoglobin A1c (HbA1c) Test
Global Gestational Diabetes Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Dietary Changes & Lifestyle Modification
- Insulin Therapy
- Oral Medications
- Continuous Glucose Monitoring (CGM)
- Physical Activity Programs
Global Gestational Diabetes Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Diagnostic Laboratories
- Homecare Settings
- Maternity Clinics
Global Gestational Diabetes Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Gestational Diabetes Market Size & CAGR (2026-2033)
- North America (Diagnosis Type, Treatment Type, End User, Distribution Channel)
- US
- Canada
- Europe (Diagnosis Type, Treatment Type, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Diagnosis Type, Treatment Type, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Diagnosis Type, Treatment Type, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Diagnosis Type, Treatment Type, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Becton Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dexcom, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ascensia Diabetes Care Holdings AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Baxter International Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- OmniPod (Insulet Corporation)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- B. Braun Melsungen AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Tandem Diabetes Care, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Global Diabetes Supply
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Edgepark Medical Supplies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- National Diabetes Supplies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
